Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Explore the cutting-edge field of T cell receptor (TCR) engineered T cell therapy in this 26-minute webinar presented by Dr. Kristin Anderson, Assistant Professor of Microbiology, Immunology and Cancer Biology at the University of Virginia. Discover how advances in cell and gene therapy have led to FDA-approved adoptive cell therapies for treating both hematological malignancies and solid tumors. Learn about the revolutionary potential of engineered cellular therapies that can unleash the true killing potential of cytotoxic T cells, allowing T cell responses to be engineered with desired specificity, avidity and function regardless of the endogenous T cell repertoire. Examine how T cells expressing tumor/self-antigen-targeting chimeric antigen receptors or high-affinity T cell receptors can be enhanced for improved tumor homing, proliferation, persistence, and antitumor function. Gain insights into recent milestones in the immune-oncology field and understand the future challenges facing engineered T cell therapy, with particular focus on TCR-engineered T cells and their translation into treatment protocols for patients.
